European countries with small populations can obtain low prices for drugs: Lithuania as a case history

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 3, 2011, Pages 343-349

  Garuoliene, Kristina ^a,b   Godman, Brian ^c,d,e   Gulbinovič, Jolanta ^a   Wettermark, Björn ^e,f   Haycox, Alan ^d  

^a VILNIUS UNIVERSITY   (Lithuania)

^b National Health Insurance Fund   (Lithuania)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^e KAROLINSKA INSTITUTE   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

generics; pharmaceutical pricing; population sizes; reform

Indexed keywords

ATORVASTATIN; CITALOPRAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEPRAZOLE; QUINAPRIL; RAMIPRIL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIMVASTATIN;

AMBULATORY CARE; ARTICLE; COST CONTROL; DRUG COST; DRUG LEGISLATION; EUROPE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; LITHUANIA; OBSERVATIONAL STUDY; PRESCRIPTION; REIMBURSEMENT; VALIDITY;

AMBULATORY CARE; DRUG COSTS; DRUGS, GENERIC; EUROPE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; LITHUANIA; POPULATION; REIMBURSEMENT MECHANISMS;

EID: 79959269131     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.24     Document Type: Article

References (38)

1. Barry M, Usher C, Tilson L. Public drug expenditure in the Republic of Ireland. Expert Rev. Pharmacoeconomics Outcomes Res. 10, 239-245 (2010)
2. Coma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Rev. Pharmacoeconomics Outcomes Res. 9, 569-581 (2009)
3. Godman B, Bucsics A, Burkhardt T et al. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomics Outcomes Res. 8, 357-371 (2008)
4. Sermet C, Andrieu V, Godman B et al. Ongoing pharmaceutical reforms in France; considerations for other countries and implications for key stakeholder groups in France. Appl. Health Econ. Health Policy 8, 7-24 (2010)
5. Simoens S. Developing competitive and sustainable Polish generic medicines market. Croat. Med. J. 50, 440-448 (2008)
6. Godman B, Shrank W, Wettermark B et al. Use of generics - a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470-2494 (2010)
7. Godman B, Shrank W, Andersen M et al. Comparing policies to enhance the utilisation generics across Europe: impact and global implications. Expert Rev. Pharmacoeconomics Outcomes Res. 10, 707-722 (2010)
8. Garattini S, Bertele V, Godman B et al. Enhancing the rational use of new medicines across European healthcare systems - a position paper. Eur. J. Clin. Pharmacol. 64, 1137-1138 (2008)
9. Gumbs P, Verschuren W, Souverein P et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br. J. Clin. Pharmacol. 64, 680-685 (2007)
10. Lee T, Emanuel E. Tier 4 drugs and the fraying of the social compact. N. Engl. J. Med. 359, 333-335 (2008)
11. Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol. 1, 1-16 (2011)
12. Barrett A, Roques T, Small M, Smith R. How much will Herceptin really cost? BMJ 33, 1118-1120 (2006)
13. Traulsen J, Almarsdóttir A. The argument for pharmaceutical policy. Pharm. World Sci. 27, 7-12 (2005)
14. McKee M, Stuckler D, Martin-Moren J. Protecting health in hard times. BMJ 341, 681-682 (2010)
15. Wettermark B, Godman B, Eriksson C et al. [Introduction of new medicines into European healthcare systems]. GGW 10(3), 24-34 (2010)
16. Godman B, Haycox A, Schwabe U et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26, 91-98 (2008)
17. Godman B, Wettermark B, Hoffman M et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoeconomics Outcomes Res. 9, 65-83 (2009)
18. Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. Pharmacoeconomics 27, 1-4 (2009)
19. Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert Rev. Pharmacoeconomics Outcomes Res. 9, 475-484 (2009)
20. McGinn D, Godman B, Lonsdale J et al. Initiatives to enhance the efficiency of statin and proton pump inhibitor prescribing in the UK; impact and implications. Expert Rev. Pharmacoeconomics Outcomes Res. 10, 73-85 (2010)
21. Simoens S. Generic medicine pricing in Europe: current issues and future perspective J. Med. Economics 11, 171-175 (2008)
22. Wettermark B, Godman B, Andersson K et al. Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. Pharmacoeconomics 26, 537-550 (2008)
23. Simoens S. International comparison of generic medicine prices. Curr. Med. Res. Opin. 23, 2647-2265 (2007)
24. Godman B, Wettermark B. Impact of reforms to enhance the quality and efficiency of statin prescribing across 20 European countries. Presented at: 9th Congress European Association for Clinical Pharmacology and Therapeutics. Edinburgh, Scotland, UK, 12-15 July 2009.
25. Godman B, Wettermark B. Trends in consumption and expenditure of proton pump inhibitors (PPIs) in 20 European countries. Presented at: 9th Congress European Association for Clinical Pharmacology and Therapeutics. Edinburgh, Scotland, UK, 12-15 July 2009.
26. Simoens S. Trends in generic prescribing and dispensing in Europe. Exp. Rev. Clin. Pharmacol. 1, 497-503 (2008)
27. Frank R. The ongoing regulation of generic drugs. N. Engl. J. Med. 357, 1993-1996 (2007)
28. Jack A. Balancing big pharma's books. Br. Med. J. 336, 418-419 (2008)
29. Moon J, Flett A, Godman B et al. Getting better value from the NHS drug budget. Br. Med. 341, c6449 (2010)
30. Kaduševičius E, Mikučionyte L, Mačiulaitis R et al. Trends in the consumption of antidepressant drugs in Lithuania in 2002-2004. Medicina 42, 1020-1029 (2006).
31. Vlahović-Palcevski V, Gantumur M, Radoševic N et al. Coping with changes in the defined daily dose in a longitudinal drug consumption database. Pharm. World Sci. 32, 125-129 (2010)
32. Godman B, Sakshaug S, Berg C et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. Pharmacoeconomics Outcomes Res. 11, 121-129 (2011)
33. Seiter A. A Practical Approach to Pharmaceutical Policy. The World Bank. Washington DC, USA (2010)
34. Martikainen J, Kivi I, Linnosmaa I. European prices of newly launched reimbursable pharmaceuticals - a pilot study. Health Policy 74, 235-246 (2005)
35. Frank R, Salkever D. Generic entry and pricing of pharmaceuticals. J. Econ. Manag. Strategy 6, 75-90 (1997)
36. Danzon PM, Chao LW. Cross-national price differences for pharmaceuticals: how large, and why? J. Health Econ. 19, 159-195 (2000)
37. Wladysiuk M, Araszkiewicz A, Godman B et al. Patient co-payments do influence atypical antipsychotic choice in Poland: implications once generic atypcials are available. Appl. Health Econ. Health Policy 9, 101-110 (2011)
38. Godman B, Buscics A, Burkhardt T et al. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries. Expert Rev. Pharmacoeconomics Outcomes Res. 10, 199-207 (2010).s